You’ve more than likely heard of Elagolix, but have you heard of Relugolix? It’s a GnRH antagonist. And, yes, it’s the same classification of drug as Abbvie’s Elagolix (aka Orlissa). It’s being groomed to treat fibroids, prostate cancer, and (yep, you guessed it) Endometriosis pain.
Although not yet approved here in the United States, Japan approved Relugolix in January 2019 to treat uterine fibroids under the name Relumina. According to an Amsterdam company, TheSocialMedNework, Relumina is available for $1,400 for a box of 100 tablets (the standard dosage is one 40-mg tablet per day). I’m curious how that price rate would change in the United States if it were ever approved. It is expected that the FDA will receive an application for approval to treat uterine fibroids later this year.
As many of you know, I was on Lupron Depot for six months for my Endometriosis. I wrote about my personal experiences and also how my life had changed after my last injection (and have also shared other’s experiences).
Recently, a friend of mine learned he will be starting Lupron Depot to treat his prostate cancer. My husband was surprised this morning when I told him. He didn’t realize the drug’s original purpose was to treat cancer…in men! And it’s because of the connection with cancer that many people think Lupron Depot is chemotherapy. It isn’t.
Today’s story is a bit different. Meet, Terry, a 72-year-old man from California. Terry was diagnosed with prostate cancer and was prescribed Lupron Depot as part of his treatment. He would like to share his experience with us today, as well as pose a question to all of you: